Literature DB >> 28075174

Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.

Sergio Ita1,2, Mayara R Agostinho1,3, Katherine Sullivan1, Seung Yub Han1, Rana Akleh1, Welkin E Johnson1, Ismael Ben F Fofana1.   

Abstract

We have constructed a single chain fragment variable (scFv) phage display library from a simian immunodeficiency virus (SIV)-infected rhesus macaque that developed unusually high-titer neutralizing antibody responses against tier-3, neutralization-resistant SIVmac239. The library was screened using trimeric (gp140) and monomeric (gp120) forms of the SIVmac239 envelope (Env) glycoprotein. We also cloned variable-heavy and variable-light (VH-VL) antibody fragments from seven previously described rhesus macaque B-cell lines (BLCLs) that produce SIV gp120-specific monoclonal antibodies (mAbs). Thirty-two gp140-specific mAbs were selected along with 20 gp120-specific ones. gp120-specific mAbs were only from the VH4 family, while gp41-specific mAbs were primarily from VH1, followed by VH4 and VH3. Rhesus macaque BLCL-derived mAbs belonged primarily to the VH4 family of antibodies followed by VH3 and a smaller number of VH1s. A preferential VH combination with Vλ light chain was observed with phage display-selected SIV Env-specific mAbs (gp120 and gp140), but not with BLCL-derived antibodies or the unpanned library. None of the tested antibodies had detectable neutralizing activity against tier-3 SIVmac239. The majority of gp120-specifc mAbs potently neutralized tier-1 SIVmac316 with 50% inhibitory concentration (IC50) values below 1 μg/ml. For gp140-specific antibodies, which were all specific for the gp41-subunit, 2 out of 11 tested neutralized SIVmac316 (IC50 of 7 and 5 μg/ml, respectively). These data suggest an order of preferential VH segment usage for SIV-specific antibodies in rhesus macaques. These antibodies will be useful in assessing the contribution of non-neutralizing antibodies to inhibition of SIV infection in vitro and in vivo.

Entities:  

Keywords:  SIV; VH usage; antibodies; envelope; phage display

Mesh:

Substances:

Year:  2017        PMID: 28075174      PMCID: PMC5749048          DOI: 10.1089/AID.2016.0247

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  30 in total

1.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

2.  Diversity of envelope genes from an uncloned stock of SIVmac251.

Authors:  Jacqueline G Bixby; Olga Laur; Welkin E Johnson; Ronald C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  2010-09-13       Impact factor: 2.205

3.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

4.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

5.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus.

Authors:  K Mori; D J Ringler; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

6.  Production and characterization of SIV envelope-specific rhesus monoclonal antibodies from a macaque asymptomatically infected with a live SIV vaccine.

Authors:  J E Robinson; K S Cole; D H Elliott; H Lam; A M Amedee; R Means; R C Desrosiers; J Clements; R C Montelaro; M Murphey-Corb
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-20       Impact factor: 2.205

Review 7.  High affinity, developability and functional size: the holy grail of combinatorial antibody library generation.

Authors:  Dirk Ponsel; Julia Neugebauer; Kathrin Ladetzki-Baehs; Kathrin Tissot
Journal:  Molecules       Date:  2011-05-03       Impact factor: 4.411

8.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

9.  Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

Authors:  Susan Zolla-Pazner; Allan C deCamp; Timothy Cardozo; Nicos Karasavvas; Raphael Gottardo; Constance Williams; Daryl E Morris; Georgia Tomaras; Mangala Rao; Erik Billings; Phillip Berman; Xiaoying Shen; Charla Andrews; Robert J O'Connell; Viseth Ngauy; Sorachai Nitayaphan; Mark de Souza; Bette Korber; Richard Koup; Robert T Bailer; John R Mascola; Abraham Pinter; David Montefiori; Barton F Haynes; Merlin L Robb; Supachai Rerks-Ngarm; Nelson L Michael; Peter B Gilbert; Jerome H Kim
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

10.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.

Authors:  Andrew T McGuire; Sam Hoot; Anita M Dreyer; Adriana Lippy; Andrew Stuart; Kristen W Cohen; Joseph Jardine; Sergey Menis; Johannes F Scheid; Anthony P West; William R Schief; Leonidas Stamatatos
Journal:  J Exp Med       Date:  2013-03-25       Impact factor: 14.307

View more
  3 in total

Review 1.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

2.  Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4.

Authors:  Hugh C Welles; Hannah A D King; Leonard Nettey; Nicole Cavett; Jason Gorman; Tongqing Zhou; Yaroslav Tsybovsky; Renguang Du; Kaimei Song; Richard Nguyen; David Ambrozak; Amy Ransier; Chaim A Schramm; Nicole A Doria-Rose; Adrienne E Swanstrom; James A Hoxie; Celia LaBranche; David C Montefiori; Daniel C Douek; Peter D Kwong; John R Mascola; Mario Roederer; Rosemarie D Mason
Journal:  PLoS Pathog       Date:  2022-06-16       Impact factor: 7.464

3.  Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries.

Authors:  Seung Yub Han; Alesia Antoine; David Howard; Bryant Chang; Woo Sung Chang; Matthew Slein; Gintaras Deikus; Sofia Kossida; Patrice Duroux; Marie-Paule Lefranc; Robert P Sebra; Melissa L Smith; Ismael Ben F Fofana
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.